RxDoctor Payments Data

Nishant Shah, MD

Cardiovascular Disease · Durham, NCNPI 1457601106

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $48,098 of the $56,523 with a category attached, or 85.1%. 13 manufacturers reported payments, led by Novartis at 53.5% of the total. 2025 is the largest year on record at $22,142, 7.2 times the $3,083 reported in 2021. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,523in general payments, 2019–2025

Across 71 payments — averaging $796.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$30K
  • Amgen$5K
  • Regeneron Healthcare Solutions, Inc.$5K
  • Premier Healthcare Solutions, Inc.$4K
  • Regeneron$4K
  • Merck$3K
  • plus $5K from 7 others
$3,486,303in research payments, 2019–2025

Across 38 payments — averaging $91,745 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$3.2M
  • Novartis$226K
  • Alnylam Pharmaceuticals Inc.$81K
  • Eli Lilly$132

What the payments were for

  • Consulting fees$48,09885%
  • Speaking & faculty fees$2,8405%
  • Travel & lodging$2,4904%
  • Food & beverage$3,0955%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,523 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$117,849
Medicare patients
722
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab181$169,689
Praluent PenAlirocumab46$48,594
OzempicSemaglutide20$39,074
JardianceEmpagliflozin25$32,594
EliquisApixaban14$21,970
Repatha SyringeEvolocumab16$11,388
Ezetimibe96$2,565
Atorvastatin Calcium98$1,513
Rosuvastatin Calcium107$1,040
Metoprolol Succinate39$664
Amlodipine Besylate59$417
Isosorbide Mononitrate ErIsosorbide Mononitrate19$308
Lisinopril29$266
Hydralazine Hcl17$226
Losartan Potassium27$182

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →